Effektivnost' terapii lerkanidipinom pri arterial'noy gipertenzii u pozhilykh
- Authors: Chikhladze NM1
-
Affiliations:
- Issue: Vol 9, No 3 (2012)
- Pages: 29-33
- Section: Articles
- URL: https://journals.eco-vector.com/2075-082X/article/view/33174
- DOI: https://doi.org/10.26442/SG33174
- ID: 33174
Cite item
Full Text
Abstract
References
- Basile J. Hypertension in the elderly: a review of the importance of systolic blood pressure elevation. J Clin Hypertens (Greenwich) 2002; 4 (2): 108-12, 119.
- Neaton JD, Killer L, Stamler J et al. Impact of systolic and diastolic blood pressure on cardiovascular mortality. In: Laragh JH, Brenner BM, eds. Hypertension: pathophysiology, diagnosis and management. 2nd ed. New York: Raven Press 1995; 1: 127-44.
- Pinto E. Blood pressure and ageing. Postgrad Med J 2007; 83 (976): 109-14.
- Pedelty L, Gorelick PB. Management of hypertension and cerebrovascular disease in the elderly. Am J Med 2008; 121 (Suppl. 8): 23-31.
- Beckett N, Peters R, Fletcher A et al. The HYVET Study group. Treatment of hypertension in patients 80 years of age or older. N Eng J Med 2008; 358: 1887-98.
- Lithell H, Hanson L, Skoog I et al. SCOPE study group. The study on cognition and prognosis in elderly (SCOPE). Principal results of a randomized double-blind intervention trial. J Hypertens 2003; 21: 875-86.
- Диагностика и лечение артериальной гипертензии. Рекомендации Российского медицинского общества по артериальной гипертонии и Всероссийского научного общества кардиологов (4-й пересмотр). Системные гипертензии 2010; 3: 5-26.
- Kaplan N. Systolic hypertension: risk management. Hoboken. NJ: John Wiley & Sons 2004.
- Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final resultsof the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group. JAMA 1991; 265 (24): 3255-64.
- Staessen JA, Fagard R, Thijs L et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet 1997; 350 (9080): 757-64.
- Guarneri L, Angelico P, Ibba M et al. Pharmacological in vitro studies of the new 1,4-dihydropyridine calcium antagonist lercanidipine. Arzneimittelforschung 1996; 46: 15-24.
- Angelico P, Guarneri L, Leonardi A et al. Vascular-selective effect of lercanidipine and other 1,4-dihydropyridines in isolated rabbit tissues. J Pharm Pharmacol 1999; 51: 709-14.
- Borghi С. Lercanidipine in hypertensionVascular Health and Risk Management 2005; 1 (3): 173-82.
- Policicchio D, Magliocca R, Malliani A. Efficacy and tolerability of lercanidipine in patients with mild to moderate essential hypertension: a comparative study with slow-release nifedipine. J Cardiovasc Pharmacol 1997; 29 (Suppl. 2): 31-5.
- Romito R, Pansini MI, Perticone F et al. Comparative effect of of lercandipine, felodipine and nifedipine GITS on blood pressure and heart rate in patients with mild to moderate arterial hypertension: the Lercandipine in Adults (LEAD) study. J Clin Hypertens 2003; 5 (4): 249-53.
- Pedrinelli R, Dell'Omo G, Nuti M et al. Heterogenous effect of calcium antagonists on leg oedema: a comparison of amlodipine versus lercanidipine in hypertensive patients. J Hypertens 2003; 21: 1969-73.
- Cavallini A, Terzi G. Effects of antihypertensive therapy with lercanidipine and verapamil on cardiac electrical activity in patients with hypertension: a randomized, double-blind pilot study. Curr Ther Res 2000; 61 (7): 477-87.
- Barrios V, Navarro A, Esteras A et al. Antihypertensive efficacy and tolerability of lercanidipine in daily clinical practice. The ELYPSE Study. Eficacia de Lercanidipino y su Perfil de Seguridad. Blood Press 2002; 11: 95-100.
- Marx A, Lichtenthal A, Milbredt C et al. Effect of anthypertensive therapy with a new third generation calcium antagonist lercanidipine on patients with concomitant diseases. J Hypertens 2004; 22 (Suppl. 2): 236.
- Robles NR, Ocon J, Gomez CF et al. Lercanidipine in patients with chronic renal failure: The ZAFRA study. Ren Fail 2005; 27: 73-80.
- Sarafidis P, Lasaridis A, Hatzistavri L et al. The effect of telmisartan and lercanidipine on blood pressure and insulin resistance in hypertensive patients. Rev Clin Pharmacol Pharmacokinet Int 2004; 18: 60-6.
- Ninci MA, Magliocca R, Malliani A. Efficacy and tolerability of lercanidipine in elderly patients with mild to moderate hypertension in a placebo-controlled, double-blind study. J Cardiovasc Pharmacol 1997; 29: S40-4.
- Poncelet P, Ribstein J, Goullard L et al. Efficacy and acceptability of lercanidipine are not age dependent in patients with essential hypertension: the AGATE study. Ann Cardiol Angeiol (Paris) 2004; 53: 123-30.
- Martell N, Lopez-Eady MD, Castro P et al. Modifications of the pulse pressure in elderly hypertensives treated with lercanidipine. J Hypertens 2004; 22 (Suppl. 2): 121.
- Roma J, Sobrino J, Soler-Amigo J et al. Treatment with lercanidipine during six months in hypertensive elderly patients (more than sixty years). J Hypertens 2004; 20 (Suppl. 4): 391.
- Leonetti G, Magnani B, Pessina AC et al. Tolerability of long-term treatment with lercanidipine versus amlodipine and lacidipine in elderly hypertensives. Am J Hypertens 2002; 15: 932-40.
- Cherubini A, Fabris F, Ferrari E et al. Comparative effects of lercanidipine, lacidipine, and nifedipine gastrointestinal therapeutic system on blood pressure and heart rate in elderly hypertensive patients: the ELderly and LErcanidipine (ELLE) study. Arch Gerontol Geriatr 2003; 37: 203-12.
- Puig JG, Calvo C, Luurila O et al. Lercanidipine, enalapril and their combination in the treatment of elderly hypertensive patients: placebo-controlled, randomized, crossover study with four ABPM. Journal of Human Hypertension 2007; 21: 917-24.
- Schwinger RHG, Schmidt-Mertens A. The new lipophillic calcium channel blocker lercanidipine combines high antihypertensive efficacy with low side effects. Dtsch Med Wochenschr 2002; 127 (Suppl. 1): S13.
- Morisco C, Trimarco B. Efficacy and tolerability of lercanidipine in comparison to and in combination with atenolol in patients with mild to moderate hypertension in a double blind controlled study. J Cardiovasc Pharmacol 1997; 29 (Suppl. 2): S26-30.
- Barbagallo M, Barbagallo Sangiorgi G. Efficacy and tolerability of lercanidipine in monotherapy in elderly patients with isolated systolic hypertension. Aging Clin Exp Res 2000; 12 (5): 375-9.
- Fogiri R, Malamani G, Zoppi A et al. Comparative effect of lercanidipine and nifedipine gastrointestinal therapeutic system on ankle volume and subcutaneous interstitial pressure in hypertensive patients: a double-Blind, randomized, parallel-group study. Curr Ther Res 2000; 61: 850-62.
- Borghi C, Prandin MG, Dormi A et al. Improved tolerability of the dihydropyridine calcium-channel antagonist lercanidipine: the lercanidipine challenge trial. Blood Press 2003; 12 (Suppl. 1): 1-8.
- Veronesi M, Cicero AF, Prandin MG et al. A prospective evaluation of persistence on antihypertensive treatment with different antihypertensive drugs in clinical practice. Vasc Health Risk Manag 2007; 3: 999-1005.